Fresenius Kabi to acquire Ivenix for $240m.

Fresenius Kabi, an integrated pharmaceutical company, agreed to acquire Ivenix, a developer of an infusion management platform, for $240m. “Combining Ivenix’s expertise in pump technology and software with our infrastructure, portfolio, and presence in hospital settings represents an ideal opportunity. We intend to scale the launch of Ivenix’s next-generation infusion system while driving growth opportunities in the United States. With today’s announcement, Fresenius Kabi expects to create a leading, comprehensive infusion therapy offering,” Michael Sen, Fresenius Kabi President and CEO.